endpts.com·Apr 22, 2026
Nektar Therapeutics has announced a $325 million public offering, selling approximately 3.5 million shares at $92 each. The news comes amidst rising stock for Maze Therapeutics and rumors of a Merck deal, alongside layoffs at Bristol-Myers Squibb.
The content does not provide relevant insights specific to your areas of interest in healthtech, biotech, or digital health. It mainly discusses financial offerings and stock movements in the biopharma industry, which might not be actionable for your focus on healthtech innovations and digital health advancements.